Distribution of tumor-infiltrating immune cells in glioblastoma.

Q1 Medicine CNS Oncology Pub Date : 2018-12-01 Epub Date: 2018-10-09 DOI:10.2217/cns-2017-0037

Enrique Orrego, Carlos A Castaneda, Miluska Castillo, Luis A Bernabe, Sandro Casavilca, Arnab Chakravarti, Wei Meng, Pamela Garcia-Corrochano, Maria R Villa-Robles, Rocio Zevallos, Omar Mejia, Pedro Deza, Carolina Belmar-Lopez, Luis Ojeda

{"title":"Distribution of tumor-infiltrating immune cells in glioblastoma.","authors":"Enrique Orrego, Carlos A Castaneda, Miluska Castillo, Luis A Bernabe, Sandro Casavilca, Arnab Chakravarti, Wei Meng, Pamela Garcia-Corrochano, Maria R Villa-Robles, Rocio Zevallos, Omar Mejia, Pedro Deza, Carolina Belmar-Lopez, Luis Ojeda","doi":"10.2217/cns-2017-0037","DOIUrl":null,"url":null,"abstract":"Aim: Evaluation of features related to infiltrating immune cell level in glioblastoma.Methods: Tumor-infiltrating lymphocytes (TILs) through H&E staining, and TILs (CD3, CD4, CD8 and CD20) and macrophage (CD68 and CD163) levels through immunohistochemistry were evaluated through digital analysis.Results: CD68 (9.1%), CD163 (2.2%), CD3 (1.6%) and CD8 (1.6%) had the highest density. Higher CD4+ was associated with unmethylated MGMT (p = 0.016). Higher CD8+ was associated with larger tumoral size (p = 0.027). Higher CD163+ was associated with higher age (p = 0.044) and recursive partitioning analysis = 4. Women (p < 0.05), total resection (p < 0.05), MGMT-methylation (p < 0.001), radiotherapy (p < 0.001), chemotherapy (p < 0.001) and lower CD4+ (p < 0.05) were associated with longer overall survival.Conclusion: Macrophages are more frequent than TILs. Some subsets are associated with clinical features.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/58/cns-07-21.PMC6331699.pdf","citationCount":"40","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2017-0037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/10/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 40

Abstract

Aim: Evaluation of features related to infiltrating immune cell level in glioblastoma.

Methods: Tumor-infiltrating lymphocytes (TILs) through H&E staining, and TILs (CD3, CD4, CD8 and CD20) and macrophage (CD68 and CD163) levels through immunohistochemistry were evaluated through digital analysis.

Results: CD68 (9.1%), CD163 (2.2%), CD3 (1.6%) and CD8 (1.6%) had the highest density. Higher CD4⁺ was associated with unmethylated MGMT (p = 0.016). Higher CD8⁺ was associated with larger tumoral size (p = 0.027). Higher CD163⁺ was associated with higher age (p = 0.044) and recursive partitioning analysis = 4. Women (p < 0.05), total resection (p < 0.05), MGMT-methylation (p < 0.001), radiotherapy (p < 0.001), chemotherapy (p < 0.001) and lower CD4⁺ (p < 0.05) were associated with longer overall survival.

Conclusion: Macrophages are more frequent than TILs. Some subsets are associated with clinical features.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤浸润免疫细胞在胶质母细胞瘤中的分布。

目的:探讨胶质母细胞瘤浸润性免疫细胞水平的相关特征。方法:通过H&E染色检测肿瘤浸润淋巴细胞(TILs)，通过数字化分析免疫组化检测肿瘤浸润淋巴细胞(TILs) (CD3、CD4、CD8、CD20)和巨噬细胞(CD68、CD163)水平。结果:CD68(9.1%)、CD163(2.2%)、CD3(1.6%)和CD8(1.6%)密度最高。CD4+升高与MGMT未甲基化相关(p = 0.016)。CD8+水平越高，肿瘤大小越大(p = 0.027)。CD163+水平越高，年龄越大(p = 0.044)，递归划分分析= 4。结论:巨噬细胞多于TILs。一些子集与临床特征有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊